Clinical Trials Directory

Trials / Completed

CompletedNCT02585401

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Evaluation of Physician Knowledge of Key Safety Information for Eylea in Canada: An Observational Postauthorization Safety Study

Status
Completed
Phase
Study type
Observational
Enrollment
99 (actual)
Sponsor
Bayer · Industry
Sex
All
Age
Healthy volunteers
Accepted

Summary

The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Detailed description

The source of information for the study will be self-reported data collected from physicians using standard questionnaires with closed-ended response choices. Questionnaires for physicians will be developed and tested using best practices for instrument development. The questions will be tailored to the study aims and the information provided in the the vial preparation instruction card, the intravitreal injection procedure video, and the Eylea product monograph. Other questions will obtain information needed to assess potential differences across subgroups and identify any biases (e.g., demographics, experience with Eylea). The questionnaire will be tested through cognitive interviews with physicians. Questionnaires will be tested in local languages, to assure that the introductory material, consent forms, and questionnaire items (question stems and response choices) are culturally appropriate and easily and correctly understood by individuals similar to those who will participate

Conditions

Interventions

TypeNameDescription
DRUGEylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Timeline

Start date
2016-02-18
Primary completion
2016-03-31
Completion
2016-05-19
First posted
2015-10-23
Last updated
2017-03-21

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02585401. Inclusion in this directory is not an endorsement.